New hope for Hard-to-Treat prostate cancer: early trial shows promise
NCT ID NCT06104449
First seen Nov 01, 2025 · Last updated May 14, 2026 · Updated 27 times
Summary
This early-stage study tested a new drug called opevesostat (MK-5684) in 7 Japanese men with a type of advanced prostate cancer that no longer responds to standard hormone therapy. The main goals were to check the drug's safety and how the body processes it. All participants had already tried other treatments, including chemotherapy.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC CASTRATION-RESISTANT PROSTATE CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
National Cancer Center Hospital East ( Site 0001)
Kashiwa, Chiba, 277-8577, Japan
-
Toho University Sakura Medical Center ( Site 0003)
Sakura, Chiba, 285-8741, Japan
-
Yokohama City University Medical Center ( Site 0002)
Yokohama, Kanagawa, 232-0024, Japan
Conditions
Explore the condition pages connected to this study.